Patents for A61P 35 - Antineoplastic agents (221,099)
05/2008
05/14/2008CN101176708A Carmofur sustained-release implantation agent for curing entity tumour
05/14/2008CN101176707A Carmustine sustained-release implantation agent for curing entity tumour
05/14/2008CN101176706A Temperature control sustained-release injection containing resist metabolism series medicine
05/14/2008CN100387724C Method for preparing extract of sophorae fructus containing high concentration of aglycone by hot water extraction
05/14/2008CN100387716C Preparation of KTV series products for inhibiting tumor cell growth and use
05/14/2008CN100387713C Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same
05/14/2008CN100387710C Therapy for primary and metastatic cancers
05/14/2008CN100387706C Epothilone -a microtubule stabilizer for treating tumor and blood vessel restenosis
05/14/2008CN100387703C Fatly phospho embrella Pa-I.H bacterial strain and method of culturing fatty phospho embrella and medicine made from its active component
05/14/2008CN100387621C Production of antihuman antigen receptors and use thereof
05/14/2008CN100387619C Regulatory/unfolding peptides of ezrin
05/14/2008CN100387616C Method for obtaining antigenic structures enhancing specific cross reactivity
05/14/2008CN100387609C Novel antibiotic preparing process
05/14/2008CN100387603C Eremophil dilactone natural product with tumour cell growth inhibiting activity
05/14/2008CN100387602C Chelerythrine compound and its preparing method
05/14/2008CN100387597C Amide substituted imidazopyridines
05/14/2008CN100387589C Flavanone compound and uses thereof
05/14/2008CN100387587C Process for separating purifying actived tea polyphenols
05/14/2008CN100387302C Folacin-starch nanometer granule, its preparation method and application
05/14/2008CN100387292C Chinese medicine preparation for treating leukemia
05/14/2008CN100387279C Chinese medicine preparation for treating malignant tumor
05/14/2008CN100387275C Oral Chinese medicine composition for treating malignant tumor
05/14/2008CN100387262C Hedyotis herba powder injection
05/14/2008CN100387243C Quality control method of ixeris sonchifolia injection
05/14/2008CN100387240C An extract of faeces bombycis
05/14/2008CN100387234C Medicine containing forrest silk vine root orherb aglycone, and its preparing method and use
05/14/2008CN100387226C Cepharanthine oral disintegration tablet and its preparing method
05/14/2008CN100387126C Method of increasing content of flavonoids and phenolic substances in plants
05/13/2008US7371845 MAGE-A3 peptides presented by HLA class II molecules
05/13/2008US7371835 p53-dependent apoptosis-inducing protein and method of screening for apoptosis regulator
05/13/2008US7371832 Polynucleotides encoding molecules associated with cell proliferation
05/13/2008US7371826 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity
05/13/2008US7371820 Nutraceuticals for the treatment, protection and restoration of connective tissues
05/13/2008US7371819 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction
05/13/2008US7371813 Method for use of IGF-binding protein for selective sensitization of target cells in vivo
05/13/2008US7371780 For combination with taxanes and anthracyclines; photodynamic therapy; for uterine/breast cancer
05/13/2008US7371777 Such as 2-(3-{[(4-ethoxybenzoyl)amino]methyl}-4-ethoxybenzyl)-tetrahydro-2-furancarboxylic acid; antihyperglycemia and antihyperlipemia action
05/13/2008US7371773 2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile; drug transporter, which actively transports an anticancer drug out of cancer cells, antagonist; improve drug resistance; anticarcinogenic agent; enhance bioavailability of anticancer drug
05/13/2008US7371766 Curcumin analogs with anti-tumor and anti-angiogenic properties
05/13/2008US7371765 Quinoline derivatives having VEGF inhibiting activity
05/13/2008US7371754 Tyrosine kinase inhibitors
05/13/2008US7371753 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
05/13/2008US7371750 Compounds and compositions as protein kinase inhibitors
05/13/2008US7371747 Cyanoalkylamino derivatives as protease inhibitors
05/13/2008US7371744 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
05/13/2008US7371742 Destroying tumor, viruses, bacteria cells ; retinoblastmas therapy
05/13/2008US7371735 Inhibitor oligonucleotides and their use for specific repression of a gene
05/13/2008US7371723 Therapeutic agents comprising pro-apoptotic proteins
05/13/2008US7371574 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
05/13/2008US7371543 Factor VII or VIIa-like molecules
05/13/2008US7371404 Amphoteric liposomes and their use
05/13/2008US7371383 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
05/13/2008US7371382 Grafting antibodies to nucleic acids; anticancer agents, osteoporosis, vision defects, antiinflammatory agents, skin disorders
05/13/2008US7371379 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents
05/13/2008US7371373 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability
05/13/2008US7371371 Interleukin-2 mutants with reduced toxicity
05/13/2008US7371370 Using colony stimulating factor comprising amino acid sequence variation as therapeutic tools in treatment and prevention of hematopoietic, neurological or reproduction disorders
05/13/2008CA2437814C Human monoclonal antibodies to fc alpha receptor (cd89)
05/13/2008CA2360833C Reovirus for the treatment of cellular proliferative disorders
05/13/2008CA2323414C Cytostatic agents
05/13/2008CA2315239C Nucleotide and protein sequence of mammastatin and methods of use
05/13/2008CA2255856C Therapeutic uses for an aminosterol compound
05/13/2008CA2234794C Novel antiproliferative protein from bacillus thuringiensis var. thuringiensis
05/13/2008CA1341573C Recombinant gamma interferons having enhanced stability and methods therefor
05/08/2008WO2008055233A1 Protein kinase inhibitors
05/08/2008WO2008054749A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
05/08/2008WO2008054702A1 Anilinopiperazine derivatives and methods of use thereof
05/08/2008WO2008054701A1 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
05/08/2008WO2008054639A2 Use of a catechin or polyphenol to treat ocular diseases and infection
05/08/2008WO2008054594A2 Method for controlling angiogenesis in animals
05/08/2008WO2008053913A1 Sulfonylurea derivative capable of selectively inhibiting mmp-13
05/08/2008WO2008053909A1 Agent for controlling growth and/or differentiation of mesenchymal stem cell
05/08/2008WO2008053863A1 Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
05/08/2008WO2008053861A1 Novel compound having 1,4-benzoxazin-3-one skeleton
05/08/2008WO2008053812A1 Cyanopyridine derivative and medicinal use thereof
05/08/2008WO2008053579A1 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm
05/08/2008WO2008053573A1 Remedy for malignant neoplasm
05/08/2008WO2008053517A1 Agent for promoting in vivo dha synthesis and seaweed oil
05/08/2008WO2008053319A1 Amide resorcinol compounds
05/08/2008WO2008053301A2 Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
05/08/2008WO2008053219A2 Composition for the treatment of gastrointestinal diseases
05/08/2008WO2008053157A1 Aminoheteroaryl compounds as for the treatment of diseases mediated by c-met kinase activity
05/08/2008WO2008053136A1 2-(hetero-)aryl,4-carbonyl substituted pyrazole derivatives as inhibitors of p38 mitogen-activated protein kinase
05/08/2008WO2008053025A1 Therapeutic use of gba2
05/08/2008WO2008052974A1 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
05/08/2008WO2008052931A1 A method of administering an antitumor compound
05/08/2008WO2008052733A1 Imidazopyridazines as pi3k lipid kinase inhibitors
05/08/2008WO2008052628A1 Triazabenzo[e]azulene derivatives for the treatment of tumors
05/08/2008WO2008052444A1 Compounds with a six-membered heterocyclic ring, their preparing method and pharmaceutical use
05/08/2008WO2008052441A1 Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof
05/08/2008WO2008052322A1 Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
05/08/2008WO2008052279A1 Organo-arsenoxide compounds and use thereof
05/08/2008WO2008052277A1 Crystalline composition of gm-csf/gm-csfr
05/08/2008WO2008052238A1 Treatment of urological cancer
05/08/2008WO2008039359A3 Bicyclic pyrimidine kinase inhibitors
05/08/2008WO2008036308A3 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
05/08/2008WO2008035365A8 Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy
05/08/2008WO2008026040A3 68ga-labeled peptide-based radiopharmaceuticals
05/08/2008WO2008024301A8 Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
05/08/2008WO2008016192A3 Fused heterocyclic derivative and use thereof